Radiation Therapy Guided by Dual PETCT Imaging for Adults with Recurrent or Metastatic Clear Cell Renal Cell Carcinoma

What this Trial Is About

Researchers are evaluating a new approach for adults with recurrent or metastatic clear cell renal cell carcinoma ccRCC. This study focuses on combining standard systemic therapy, including targeted therapy and anti-PD-1 immunotherapy, with advanced imaging and radiation techniques to better target cancer sites. The aim is to assess progression-free survival and local control of treated tumors, along with monitoring treatment-related side effects. All participants will receive dual PETCT scans using FDG and a CAIX-targeted tracer to map cancer lesions. When possible, visible tumors identified by these scans will be treated using image-guided stereotactic ablative radiotherapy SABR. Radiotherapy is planned to cover as many detectable lesions as feasible. This single-arm study plans to enroll about 70 patients. Participants will be followed for at least two years to evaluate how well the cancer is controlled locally and how long patients remain free from disease progression. Researchers will also track the duration of current systemic therapy until treatment changes are needed due to cancer growth. Safety and side effects related to the treatments will be monitored throughout the study period, which may last up to three years for some measures.

CAIX PET/ CT Guided Radiation Therapy in CcRCC.